Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Podcast 42: CDMO/CMO Mid-Year Review: Tracking the Key Moves Thus Far in 2023 

As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an inside look on what is on the industry’s radar.

Key topics: (see Chapter Markers in drop down menu in audio player above) 

  • Baxter (1:26)
  • Samsung Biologics (3:10)
  • Lotte Biologics (4:37)
  • Fujifilm Diosynth Biotechnologies (6:44)
  • Lonza (9:09)
  • WuXi Biologics (11:14)
  • Bachem (14:15)
  • Agilent Technologies (15:36)
  • WuXi STA (16:12)
  • CordenPharma (17:21)
  • eureKING (18:50)
  • NewBiologix (20:43)
  • Ascend Gene & Cell Therapies (21:38)

Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show  

You May Also Like

Podcast 44: What’s Trending: Parenteral Drug Development & Manufacturing

What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights…

Podcast 43: CDMOs/CMOs: The Movers and Shakers of 2023

As 2023 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2023? DCAT Value Chain Insights looks at which companies topped the…

Podcast 41: API Alert: EU Proposes New Requirements To Secure Pharma Supply Chains 

The European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages…

Podcast 40: The CDMO/CMO Report: Parenteral Drugs 

Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain…